Chemical Namemirabegron
Dosage FormTablet (oral; 25 mg, 50 mg); Suspension (oral; 8 mg/mL)
Drug ClassReceptor agonists
CompanyAstellas Pharma
Approval Year2012


  • For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Myrbetriq (mirabegron) Prescribing Information.2012Astellas Pharma US Inc., Northbrook, IL